| Name | Title | Contact Details |
|---|
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.
Flexion Therapeutics (NASDAQ: FLXN) is a biopharmaceutical company focused on the discovery, development & commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions. Flexion is based in Burlington, Massachusetts.
American Academy Of Pain Medicine is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
First Service Administrators is a Winter Haven, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Camtec is a Cambridge, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.